[go: up one dir, main page]

WO2011061519A3 - Topical foam composition - Google Patents

Topical foam composition Download PDF

Info

Publication number
WO2011061519A3
WO2011061519A3 PCT/GB2010/002164 GB2010002164W WO2011061519A3 WO 2011061519 A3 WO2011061519 A3 WO 2011061519A3 GB 2010002164 W GB2010002164 W GB 2010002164W WO 2011061519 A3 WO2011061519 A3 WO 2011061519A3
Authority
WO
WIPO (PCT)
Prior art keywords
foam composition
topical foam
composition
topical
rifaximin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2010/002164
Other languages
French (fr)
Other versions
WO2011061519A2 (en
Inventor
Amar Lulla
Geena Malhotra
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cipla Ltd
Original Assignee
Cipla Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP10784333.6A priority Critical patent/EP2503989A2/en
Priority to NZ600362A priority patent/NZ600362A/en
Priority to CA2781580A priority patent/CA2781580A1/en
Priority to CN2010800581391A priority patent/CN102724960A/en
Priority to JP2012540490A priority patent/JP2013511570A/en
Priority to BR112012012316A priority patent/BR112012012316A2/en
Priority to AU2010320656A priority patent/AU2010320656B2/en
Priority to MX2012005883A priority patent/MX2012005883A/en
Application filed by Cipla Ltd filed Critical Cipla Ltd
Priority to RU2012126084/15A priority patent/RU2012126084A/en
Publication of WO2011061519A2 publication Critical patent/WO2011061519A2/en
Publication of WO2011061519A3 publication Critical patent/WO2011061519A3/en
Anticipated expiration legal-status Critical
Priority to US13/959,193 priority patent/US20130315998A1/en
Priority to US14/668,455 priority patent/US20150196488A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/122—Foams; Dry foams

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A topical foam pharmaceutical composition for rectal administration comprising rifaximin is described. Also described is a method of making the composition and the use of the composition to as a medicament.
PCT/GB2010/002164 2009-11-23 2010-11-23 Topical foam composition Ceased WO2011061519A2 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
AU2010320656A AU2010320656B2 (en) 2009-11-23 2010-11-23 Topical foam composition
CA2781580A CA2781580A1 (en) 2009-11-23 2010-11-23 Topical foam composition
CN2010800581391A CN102724960A (en) 2009-11-23 2010-11-23 Topical foam composition
JP2012540490A JP2013511570A (en) 2009-11-23 2010-11-23 Foam composition for topical use
BR112012012316A BR112012012316A2 (en) 2009-11-23 2010-11-23 pharmaceutical composition for topical rectal administration in the form of foam, use of a pharmaceutical composition, method for treating, preventing or alleviating a dusturium in the rectum, colon, terminal ileum or anus, process for making a pharmaceutical composition containing rifaximin, use of a silicone and dispenser for pharmaceutical composition
MX2012005883A MX2012005883A (en) 2009-11-23 2010-11-23 Topical foam composition.
RU2012126084/15A RU2012126084A (en) 2009-11-23 2010-11-23 FOAM COMPOSITION FOR LOCAL USE
EP10784333.6A EP2503989A2 (en) 2009-11-23 2010-11-23 Topical foam composition
NZ600362A NZ600362A (en) 2009-11-23 2010-11-23 Topical foam composition
US13/959,193 US20130315998A1 (en) 2009-11-23 2013-08-05 Topical Foam Composition
US14/668,455 US20150196488A1 (en) 2009-11-23 2015-03-25 Topical Foam Composition

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2703/MUM/2009 2009-11-23
IN2703MU2009 2009-11-23

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US13511301 A-371-Of-International 2010-11-23
US13/959,193 Continuation US20130315998A1 (en) 2009-11-23 2013-08-05 Topical Foam Composition

Publications (2)

Publication Number Publication Date
WO2011061519A2 WO2011061519A2 (en) 2011-05-26
WO2011061519A3 true WO2011061519A3 (en) 2011-10-06

Family

ID=43447946

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2010/002164 Ceased WO2011061519A2 (en) 2009-11-23 2010-11-23 Topical foam composition

Country Status (12)

Country Link
EP (1) EP2503989A2 (en)
JP (1) JP2013511570A (en)
KR (1) KR20120117788A (en)
CN (1) CN102724960A (en)
AU (1) AU2010320656B2 (en)
BR (1) BR112012012316A2 (en)
CA (1) CA2781580A1 (en)
MX (1) MX2012005883A (en)
NZ (1) NZ600362A (en)
RU (1) RU2012126084A (en)
WO (1) WO2011061519A2 (en)
ZA (1) ZA201204018B (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1698630E (en) 2005-03-03 2014-09-15 Alfa Wassermann Spa New polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations
ITBO20050123A1 (en) 2005-03-07 2005-06-06 Alfa Wassermann Spa GASTRORESISTIC PHARMACEUTICAL FORMULATIONS CONTAINING RIFAXIMINA
EP1871433B1 (en) 2005-03-24 2009-04-22 NOLabs AB Cosmetic treatment with nitric oxide, device for performing said treatment and manufacturing method therefor
ES2958410T3 (en) 2009-08-21 2024-02-08 Novan Inc Topical gels
IT1398550B1 (en) 2010-03-05 2013-03-01 Alfa Wassermann Spa RIFAXIMINA COMPREHENSIVE FORMULATIONS USEFUL TO OBTAIN A PROLONGED EFFECT IN TIME
ES2804263T3 (en) 2011-07-05 2021-02-05 Novan Inc Topical compositions
ITBO20110461A1 (en) 2011-07-29 2013-01-30 Alfa Wassermann Spa PHARMACEUTICAL COMPOSITIONS INCLUDING RIFAXIMINA, PROCESSES FOR THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF VAGINAL INFECTIONS.
CN104302175B (en) 2012-03-14 2017-04-12 诺万公司 Nitric oxide releasing pharmaceutical compositions
ITBO20120368A1 (en) 2012-07-06 2014-01-07 Alfa Wassermann Spa COMPOSITIONS INCLUDING RIFAXIMINA AND AMINO ACIDS, RIFAXIMINE CRYSTALS DERIVING FROM SUCH COMPOSITIONS AND THEIR USE.
US9855211B2 (en) 2013-02-28 2018-01-02 Novan, Inc. Topical compositions and methods of using the same
WO2016022170A1 (en) 2014-08-08 2016-02-11 Novan, Inc. Topical emulsions
AU2014305778B2 (en) 2013-08-08 2019-11-21 Ligand Pharmaceuticals Incorporated Topical compositions and methods of using the same
ES2742106T3 (en) 2014-05-12 2020-02-13 Alfasigma Spa New form of solvated rifaximin crystal, production, compositions and uses thereof
JP7090549B2 (en) 2016-03-02 2022-06-24 ノヴァン，インコーポレイテッド Therapeutic compositions for inflammation and their treatment methods
EP3442502A4 (en) 2016-04-13 2019-11-06 Novan, Inc. COMPOSITIONS, SYSTEMS, KITS AND METHODS FOR TREATING INFECTION
MX391415B (en) * 2016-12-16 2025-03-21 Ferring Bv RECTAL FOAM FORMULATIONS.
EP3758679A4 (en) 2018-03-01 2021-12-15 Novan, Inc. NITRIC OXIDE RELEASING SUPPOSITORIES AND THEIR METHODS OF USE

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6140355A (en) * 1991-12-17 2000-10-31 Alfa Wassermann S.P.A. Pharmaceutical compositions containing rifaximin for treatment of vaginal infections
WO2007103448A2 (en) * 2006-03-09 2007-09-13 Salix Pharmaceuticals, Inc. Rifaximin anti-rectal dysfunction preparation
US20080063607A1 (en) * 2003-08-04 2008-03-13 Foamix Ltd Oleaginous pharmaceutical and cosmetic foam
WO2009137672A1 (en) * 2008-05-07 2009-11-12 Salix Pharmaceuticals, Ltd. Methods of treating bowel disease by administering a bowel cleanser and an antibiotic

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2907118A1 (en) 1979-02-20 1980-09-04 Schering Ag NEW PROSTACYCLINE DERIVATIVES AND METHOD FOR THE PRODUCTION THEREOF
IT1154655B (en) 1980-05-22 1987-01-21 Alfa Farmaceutici Spa IMIDAZO-RIFAMYCIN DERIVATIVES METHODS FOR THEIR PREPARATION AND USE AS AN ANTIBACTERIAL ACTION SUBSTANCE
IT1199374B (en) 1984-05-15 1988-12-30 Alfa Farmaceutici Spa PROCESS FOR THE PREPARATION OF PIRIDO-IMIDAZO-RIFAMICINE
GB8909559D0 (en) 1989-04-26 1989-06-14 Smith Kline French Lab Pharmaceutical compositions
FR2647344B1 (en) 1989-05-25 1995-06-02 Physiopharm Sarl RECTAL USE AEROSOL FOAM
US4946939A (en) 1989-05-30 1990-08-07 The Dow Chemical Company High purity polyether polyols
IT1243379B (en) 1990-07-27 1994-06-10 Giuliani Spa PHARMACEUTICAL COMPOSITION SUITABLE FOR RECTAL ADMINISTRATION OF ACTIVE PRINCIPLES WHICH EXPLICATE A MEDICATION ACTION AT THE LEVEL OF THE COLON, PREVALENTLY TOPICAL
IT1264494B1 (en) 1993-03-23 1996-09-24 Alfa Wassermann Spa USE OF RIFAXIMIN AND FORMULATIONS THAT CONTAIN IT IN THE TREATMENT OF GASTRIC DYSPEPSIES ORIGINATED BY HELICOBACTER
IT1290679B1 (en) 1997-02-14 1998-12-10 Alfa Wassermann Spa USE OF RIFAXIMINE AND OF THE PHARMACEUTICAL COMPOSITIONS THAT CONTAIN IT IN THE TREATMENT OF DIARRHEA FROM CRYPTOSPORIDIOSIS.
US7820145B2 (en) * 2003-08-04 2010-10-26 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
ITMI20032144A1 (en) 2003-11-07 2005-05-08 Alfa Wassermann Spa REFLEXIMINE POLIMORPHIC FORMS, PROCESSES TO OBTAIN THEM AND
PT1698630E (en) 2005-03-03 2014-09-15 Alfa Wassermann Spa New polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations
CN101502510B (en) * 2009-03-19 2011-11-09 山东京卫制药有限公司 Medicament composition for treating colpitis symptoms and preparation method thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6140355A (en) * 1991-12-17 2000-10-31 Alfa Wassermann S.P.A. Pharmaceutical compositions containing rifaximin for treatment of vaginal infections
US20080063607A1 (en) * 2003-08-04 2008-03-13 Foamix Ltd Oleaginous pharmaceutical and cosmetic foam
WO2007103448A2 (en) * 2006-03-09 2007-09-13 Salix Pharmaceuticals, Inc. Rifaximin anti-rectal dysfunction preparation
WO2009137672A1 (en) * 2008-05-07 2009-11-12 Salix Pharmaceuticals, Ltd. Methods of treating bowel disease by administering a bowel cleanser and an antibiotic

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"Remington:The science and pratice of pharmacy", 1 January 2000, 20000101, XP002617989 *
MILO GIBALDI, MARY LEE, ARCHANA DESAI: "Gibaldi's drug delivery systems in pharmaceutical care", 2007, AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS, article 7: "Rectal, Vaginal and Urethral delivery", pages: 98 - 98, XP002617991 *
RONALD P. EVENS: "Drug and biological development: from molecule to product and beyond", 2007, SPRINGER, USA, ISBN: 9780387329789, article PAVLIV, L.;CAHILL, J.F.: "Formulation and Manufacturing", pages: 214 - 214, XP002617990 *

Also Published As

Publication number Publication date
ZA201204018B (en) 2012-12-27
JP2013511570A (en) 2013-04-04
MX2012005883A (en) 2012-10-09
AU2010320656A1 (en) 2012-06-21
EP2503989A2 (en) 2012-10-03
NZ600362A (en) 2014-08-29
KR20120117788A (en) 2012-10-24
AU2010320656B2 (en) 2015-07-30
WO2011061519A2 (en) 2011-05-26
RU2012126084A (en) 2013-12-27
CA2781580A1 (en) 2011-05-26
CN102724960A (en) 2012-10-10
BR112012012316A2 (en) 2016-04-26

Similar Documents

Publication Publication Date Title
WO2011061519A3 (en) Topical foam composition
WO2011093825A3 (en) Effervescent dosage forms comprising cephalosporin antibiotic
WO2011061516A3 (en) Topical foam composition
WO2011131943A3 (en) Pharmaceutical compositions
WO2009085990A3 (en) Processes for the preparation of sitagliptin and pharmaceutically acceptable salts thereof
WO2014045162A8 (en) ALKYL-SUBSTITUTED HEXAHYDROPYRANO[3,4-d] [1,3]THIAZIN-2-AMINE COMPOUNDS
WO2012034079A3 (en) Macrolide dosage forms
WO2012019426A8 (en) Phthalazinone derivative, and preparation method and pharmaceutical use thereof
WO2012019430A8 (en) Phthalazinone derivative, and preparation method and pharmaceutical use thereof
WO2010092090A3 (en) Novel salts of sitagliptin
WO2012065019A3 (en) Combination comprising pyridopyrimidinone inhibitors of pi3k alpha
MY172422A (en) Pyrazole compound and pharmaceutical use thereof
WO2011009938A3 (en) Stambomycin and derivatives, their production and their use as drugs
WO2011079193A3 (en) Preparation of bendamustine and its salts
MX2012012941A (en) Novel ophthalmic compositions.
WO2012135615A3 (en) Enopeptins, uses thereof, and methods of synthesis thereto
WO2010121675A3 (en) Thiazolyl-benzimidazoles
EP3677261B8 (en) Administration of serine protease inhibitors to the stomach
WO2012074869A8 (en) Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture
WO2011064558A3 (en) Pharmaceutical composition
WO2011135581A3 (en) Pharmaceutical compositions of dronedarone
WO2010148314A3 (en) Preparation of esomeprazole and its pharmaceutically acceptable salts
WO2012018791A3 (en) Preparation of prasugrel hydrochloride
WO2009080745A3 (en) Perhydroquinoxaline derivatives as analgesics
WO2010130776A3 (en) Use of delta-tocopheryl-carbohydrate as a depigmenting agent

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201080058139.1

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10784333

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: MX/A/2012/005883

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2781580

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2012540490

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2010320656

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 4808/DELNP/2012

Country of ref document: IN

Ref document number: 2010784333

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2010320656

Country of ref document: AU

Date of ref document: 20101123

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20127016200

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2012126084

Country of ref document: RU

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112012012316

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112012012316

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20120523